Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Elliott Sigal


Mr. Elliott Sigal serves as Venture Partner and Senior Advisor at New Enterprise Associates. He joined NEA in 2014. He is a former Executive Vice President and Director of Bristol-Myers Squibb and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company's strategy in biologics and acquiring external innovation in Bristol's String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Mr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Mr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Mr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied Engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Mr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance. He is also a Board Member at Adaptimmune Therapeutics.

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Primary Office
  • Princeton, NJ
  • United States

Elliott Sigal Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Mersana Therapeutics 02-Mar-2015 Later Stage VC 0000 Drug Discovery Generating Revenue/Not Profitable 0000000 00000 00
0000000 00000000 21-Nov-2014 00000 00000 000.00 Drug Discovery Generating Revenue/Not Profitable 0000000 00000 00
00000000000 000000 19-Sep-2014 00000 00000 00000 Biotechnology Generating Revenue/Not Profitable 0000000 00000 00
To view this investor’s complete investment and acquisition history, request access »
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Elliott Sigal’s full profile, request a free trial.

Elliott Sigal Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Surface Oncology 19-Apr-2018 IPO 00000 Completed
  • Novartis Institutes for BioMedical Research
0000000 0000000000 28-Jun-2017 000 0000 Completed
00000000000 000000 06-May-2015 000 00000 Completed
To view this investor’s complete exits history, request access »

Elliott Sigal Team (1)

Name Title Deals Funds Boards Office Contact
Elliott Sigal MD Angel Investor 0 0 Princeton, NJ